Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTE Phase 2 Study of Efavaleukin Alfa in Ulcerative Colitis (Japan)
jRCT2071230044Phase 2Suspended
- Sponsor
- Amgen
- Start
- Apr 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2 trial of efavaleukin alfa in autoimmune colitis (4 arms), sponsored by Amgen. Started Apr 2023; status: suspended.
02
Drugs
efavaleukin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071230044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230044.